Halozyme Therapeutics (HALO) Other Working Capital Changes (2010 - 2026)
Halozyme Therapeutics (HALO) reported Other Working Capital Changes of $9.1 million for Q1 2026, up 82.34% year-over-year from $5.0 million in Q1 2025, and up 132.04% quarter-over-quarter from -$28.4 million in Q4 2025.
Halozyme Therapeutics (HALO) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 17 years of Other Working Capital Changes data on file, last reported at $9.1 million in Q1 2026.
- Other Working Capital Changes for Q1 2026 came in at $9.1 million, up 82.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.1 million (up 736.06% YoY), and the FY2025 annual result was $33.0 million, up 715.35% from the prior year.
- Other Working Capital Changes rose to $9.1 million in Q1 2026 per HALO's latest filing, from -$28.4 million in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $43.5 million in Q2 2024 and troughed at -$38.5 million in Q3 2024.
- A 5-year average of $2.5 million and a median of -$175000.0 in 2023 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2022 and 2024: Other Working Capital Changes soared 834.81% in 2022, then slumped 21890.29% in 2024.
- A 5-year view of Other Working Capital Changes shows it stood at $9.3 million in 2022, then plunged by 116.35% to -$1.5 million in 2023, then tumbled by 270.05% to -$5.6 million in 2024, then sank by 405.68% to -$28.4 million in 2025, then surged by 132.04% to $9.1 million in 2026.
- Business Quant data shows HALO's Other Working Capital Changes at $9.1 million in Q1 2026, -$28.4 million in Q4 2025, and $20.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.11 Mn |
| Mar 31, 2026 | 9.11 Mn |
| Dec 31, 2025 | -28.42 Mn |
| Dec 31, 2025 | -28.42 Mn |
| Sep 30, 2025 | 20.32 Mn |
| Sep 30, 2025 | 20.32 Mn |
| Jun 30, 2025 | 36.07 Mn |
| Jun 30, 2025 | 36.07 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | -5.62 Mn |
| Dec 31, 2024 | -5.62 Mn |
| Sep 30, 2024 | -38.48 Mn |
| Sep 30, 2024 | -38.48 Mn |
| Jun 30, 2024 | 43.54 Mn |
| Jun 30, 2024 | 43.54 Mn |
| Mar 31, 2024 | -4.80 Mn |
| Mar 31, 2024 | -4.80 Mn |
| Dec 31, 2023 | -1.52 Mn |
| Dec 31, 2023 | -1.52 Mn |